References
- Armitage J., Cheron B. Interpretation of clinical trials in diffuse large cell lymphoma. Journal of Clinical Oncology 1988; 6: 335–1347
- Klimo P., Conners J. MACOP‐B Chemotherapy for the treatment of diffuse large cell lymphoma. Annals of Infernal Medicine 1985; 102: 596–602
- Saven A., Piro L. D. 2–Chlorcdeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Annals of Internal Medicine 1994; 120: 784–791
- Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy‐cell leukemia induced by a single infusion of 2‐chlorodeoxyadenosine. New England Journal of Medicine 1990; 322: 1117–21
- Piro L. D., Saven A., Ellison D., Thurston D., Carson D. A., Beutler E. Prolonged complete remissions following 2‐chlorodeoxyadenosine (2‐CdA) in hairy cell leukemia (HCL) [Abstract]. Proceedings of American Society of Clinical Oncology 1992; 11: 846
- Juliusson G., Lilliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2‐chloro‐2′deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79: 888–94
- Estey E. M., Kurzrock R., Kantarjian H. M., O'Brien S., McCredie K., Beran M., et al. Treatment of hairy cell leukemia with 2‐chlorodeoxyadenosine (2‐CdAJ. Blood 1992; 79: 882–7
- Tallman M. S., Hakimian D., Variakojis D., Koslow D., Sisney G. A., Rademaker A. W., et al. A single cycle of 2‐chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 9: 2203–9
- Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2‐chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–73
- Juliusson G., Lilliemark J. High complete remission rate from 2‐chloro‐2′deoxyadenosine in previously treated patients with B‐cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. Journal of Clinical Oncology 1993; 11: 679–89
- Kay A. C., Saven A., Carrera C. J., Carson D. A., Thurston D., Beutler E., et al. 2‐chlorodeoxyadenosinc treatment of low‐grade lymphomas. Journal of Clinical Oncology 1992; 10: 371–377
- Hoffman M., Tallman M. S., Hakimian D., Janson D., Hogan D., Variakogis D., et al. 2‐chlorodeoxytidenosine is an active salvage therapy in advanced indolent non‐hodgkin' s lymphoma. Journal of Clinical Oncology 1994; 12: 788–792
- Enianuele S., Saven A., Kosty M., Ellison D., Piro L. 2‐chlorodeoxyadenosine activity in patients with untreated low grade lymphoma. [Abstract]. Proceedings of American Society of Clinical Oncology 1994; 13: 1002A
- Saven A., Emanuel S., Kohty M., Koziol J., Ellison D., Piro L. 2‐chlorodeoxyadenosine activity in patients with untreated. indolent non‐Hodpkin's lymphoma. Blood 1995; 86: 1710–1716
- Lilliemark J., Hahgerg H., Cavallin‐Stahl E., Juliusson G. Cladribine for early low grade non‐hodgkins lymphoma. [Abstract]. Blood 1994; 84: 658, suppl
- Spielberger R. T., Stock W., Larson R. A. Liateriosis after 2‐chlorodeoxyadenosine treatment. [Letter]. New England Journal of Medicine 1993; 328: 813–814
- Taylork K., Bunce I., Eliadis P., Moore D., Rentoul A., Bashford J., et al. Short infusional 2‐chlorodeoxyadeno‐sine‐effective therapy in relapsed or poor risk de novo low grade lymphoma. [Abstract]. Blood 1994; 84: 659, Suppl
- Carrera C. J., Piro L. D., Saven A., Cox K., Beutler E., Carson D. A., et al. Restoration of lymphocyte subsets following 2‐chlorodeoxyadenosine remission induction in hairy cell leukemia. [Abstract]. Blood 1990; 76(Suppl 1)1029